Core Viewpoint - Treace Medical Concepts, Inc. is set to release its financial results for Q4 and the full year of 2025 on February 27, 2026, with a conference call scheduled for 8:00 am ET to discuss these results [1]. Company Overview - Treace Medical Concepts is a medical technology company focused on improving surgical treatments for bunions and related midfoot deformities, which affect approximately 67 million Americans, with an estimated 1.1 million being surgical candidates annually [4]. - The company has developed the patented Lapiplasty 3D Bunion Correction System, which aims to correct bunion deformities in three dimensions and stabilize the affected joint, addressing the root cause of the condition [4]. - Treace also offers additional systems such as the Adductoplasty Midfoot Correction System and minimally invasive options like the Nanoplasty 3D and Percuplasty™ systems, along with the SpeedMTP System [4]. - The company is expanding its market presence by extending its SpeedPlate rapid compression implant platform and providing advanced digital solutions for pre-operative planning [4].

Fourth Quarter and Full Year 2025 Financial and Business Update February 12, 2026 Forward-Looking Statements & Legal Disclaimers This presentation and the accompanying oral commentary may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are predictions and subject to significant risks and uncertainties that could cause actual results to differ materially from those expressed or implied. Forward-looking statements may be identifie ...

Core Insights - Profound Medical Corp. will announce its fourth quarter and full year 2025 financial results on March 5, 2026, followed by a conference call to discuss the results and business developments [1][2]. Company Overview - Profound Medical Corp. is a commercial-stage medical device company focused on developing and marketing innovative interventional MRI (iMRI) procedures [3]. Product Offerings - The company is commercializing TULSA-PRO, a technology that integrates real-time MRI, AI-enhanced planning, and robotically-driven ultrasound for treating prostate diseases. The TULSA Procedure is designed to preserve urinary continence and sexual function while effectively targeting prostate tissue [4]. - TULSA-PRO is CE marked, Health Canada approved, and has received 510(k) clearance from the U.S. FDA [4]. - Profound is also marketing Sonalleve, a therapeutic platform approved for treating uterine fibroids and other conditions. It has received CE marking and FDA approval under a Humanitarian Device Exemption for specific treatments [5].

4Q 2025 Earnings Presentation February 12, 2026 1 © 2026 Artivion, Inc. FORWARD-LOOKING STATEMENT Statements made in this presentation that look forward in time or that express management's beliefs, expectations, or forecasts are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements reflect the views of management at the time such statements are made. These statements include our beliefs and expectations about our future revenu ...

Core Viewpoint - Globus Medical, Inc. will announce its financial results for Q4 and the full year ended December 31, 2025, on February 24, 2026, after market close [1] Group 1: Financial Results Announcement - The financial results will be available on the Globus Medical website [1] - A teleconference will be held to discuss the performance with the investment community at 4:30 p.m. Eastern Time on the same day [2] - Participants can access the conference call live via webcast on the Investors page of the Globus Medical website [2] Group 2: Participation Details - Telephone participants must register in advance to receive a confirmation email with details on how to join the call, including a dial-in number and unique passcode [3] - An audio archive of the call will be available on the Investors page after the event [3] Group 3: Company Overview - Globus Medical, Inc. is a leading global musculoskeletal company focused on addressing unmet clinical needs and improving lives [4] - The company emphasizes innovation, education, clinical support, and advancements in various medical fields including spine, orthopedic trauma, and joint reconstruction [4]

Dexcom earnings Q4 2025 Safe harbor statement This presentation contains "forward - looking statements" that are based on our management's beliefs and assumptions and on inform ation available to management as of February 12, 2026. We intend for such forward - looking statements to be covered by the safe harbor provisions fo r forward - looking statements contained in the U.S. Private Securities Litigation Reform Act of 1995. Forward - looking statements include informatio n concerning our possible or assum ...

Core Insights - Aethlon Medical reported its fiscal Q3 2026 financial results, highlighting advancements in clinical and research programs, operational efficiencies, and ongoing technology development [1] Financial Performance - As of December 31, 2025, Aethlon had a cash balance of approximately $7.0 million [1] - Consolidated operating expenses for Q3 2026 were approximately $2.06 million, an increase of $250,000 or 13.6% from $1.81 million in Q3 2025, primarily due to higher payroll costs [1] - For the nine months ended December 31, 2025, consolidated operating expenses were approximately $5.36 million, a decrease of approximately $1.98 million or 26.9% compared to $7.34 million in the same period in 2024 [1] Operational Efficiency - The company maintained disciplined cost controls, resulting in a 26.9% decline in operating expenses year-to-date compared to the prior year [1] - Aethlon is actively progressing in its Australian oncology trial, with Cohort 2 enrollment and treatment underway, building on favorable results from Cohort 1 [1] Technology Development - Aethlon is evaluating the Hemopurifier® compatibility with a simplified blood treatment system under a Material Transfer Agreement, which may enhance its use in oncology units [1] - The company continues to advance its preclinical extracellular vesicle (EV) research platform, with recent findings on Long COVID published and submitted for peer review [1] Scientific Advancement - The R&D team is exploring the potential of the Hemopurifier to remove various EVs implicated in diseases beyond cancer, including Lupus and Cardiovascular Diseases [1] - Aethlon's research indicates that the Hemopurifier may serve as a "pipeline within a single device" for multiple therapeutic applications [1] Clinical Progress - The ongoing Australian oncology trial aims to evaluate the safety and feasibility of Hemopurifier treatments in patients with solid tumors [1] - The trial is designed to assess appropriate dosing in participants receiving anti-PD-1 agents [1] Nasdaq Compliance - Aethlon has maintained compliance with Nasdaq listing requirements, resolving all prior compliance matters [1]

As filed with the Securities and Exchange Commission on February 12, 2026. Registration No. 333- (I.R.S. Employer Identification No.) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 BIOVENTRIX, INC. (Exact Name of Registrant as Specified in its Charter) (State or other jurisdiction of incorporation or organization) Delaware 3841 20-0372415 (Primary Standard Industrial Classification Code Number) If this Form is a post-e ...

Core Viewpoint - OrthoPediatrics Corp. is set to release its fourth quarter and full year 2025 financial results on February 26, 2026, and will host a conference call to discuss these results [1]. Company Overview - OrthoPediatrics Corp. was founded in 2006 and focuses exclusively on pediatric orthopedics, offering a comprehensive range of products to improve the lives of children with orthopedic conditions [3]. - The company markets over 85 products across three major categories: trauma and deformity, scoliosis, and sports medicine/other procedures [3]. - OrthoPediatrics has a global sales organization dedicated to pediatric orthopedics, distributing products in the United States and over 75 countries worldwide [3].

$30.0 million upfront with up to an additional $48.0 million of potential aggregate gross proceeds upon the exercise in full of milestone-linked warrants for cashOffering led by Nantahala Capital, with participation of healthcare-dedicated funds, including Broadfin Holdings, and participation from existing shareholder, Glen Taylor, and members of the Company's board of directors and managementNet proceeds extend anticipated cash runway into second half of 2027, beyond expected PMA submission; if milestone- ...